Gamida Cell Revenue and Competitors

Jerusalem, USA

Location

$267.8M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Gamida Cell's estimated annual revenue is currently $35.5M per year.(i)
  • Gamida Cell's estimated revenue per employee is $193,750
  • Gamida Cell's total funding is $267.8M.

Employee Data

  • Gamida Cell has 183 Employees.(i)
  • Gamida Cell grew their employee count by -1% last year.

Gamida Cell's People

NameTitleEmail/Phone
1
General Counsel & Chief Compliance OfficerReveal Email/Phone
2
Head Global Information TechnologyReveal Email/Phone
3
Chief Medical OfficerReveal Email/Phone
4
Director, Southwest Cellular TherapyReveal Email/Phone
5
Marketing DirectorReveal Email/Phone
6
Associate Director, Lead Case ManagerReveal Email/Phone
7
Chief Financial OfficerReveal Email/Phone
8
Regulatory Affairs Associate DirectorReveal Email/Phone
9
Associate Director, Lead Case ManagerReveal Email/Phone
10
Regional Account ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$99.4M45840%N/AN/A
#2
$20.6M13322%N/AN/A
#3
$156.1M146-70%$145MN/A
#4
$3.5M45-25%$150MN/A
#5
$1.6M210%$459.5MN/A
#6
$67.3M31016%$180.7MN/A
#7
$8.5M55-2%N/AN/A
#8
$256.3M10259%$168.5MN/A
#9
$9.1M59-9%N/AN/A
#10
$16.6M1073%N/AN/A
Add Company

What Is Gamida Cell?

Gamida Cell is a leader in cellular and immune therapeutics, committed to changing the treatment paradigm for patients with cancer and rare genetic diseases. We are building a broad pipeline based on our proprietary NAM technology platform. Our lead program, NiCord, is in phase 3 development for allogeneic bone marrow transplantation and was granted Breakthrough Therapy Designation by the FDA.

keywords:N/A

$267.8M

Total Funding

183

Number of Employees

$35.5M

Revenue (est)

-1%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Gamida Cell News

2022-04-20 - Gamida Cell Receives FDA Clearance For Lymphoma ...

GDA-201 is “an off-the-shelf cell therapy candidate for the treatment of patients with follicular and diffuse large B cell lymphomas,” Gamida...

2022-04-17 - Gamida Cell Presents Updated One-Year Post-Transplant ...

Gamida Cell Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 Study of Omidubicel at 2022 Transplantation & Cellular Therapy...

2022-04-17 - UPDATED: Gamida Cell gets IND cleared and clinical hold ...

Paul Schloesser. Associate Editor. The small Boston-based cell therapy outfit Gamida Cell recently axed 10% of its workforce in order to...

2021-10-26 - Gamida Cell to Present NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline and Update on GDA-201 at Today's Virtual R&D Day - Form 6-K

Gamida Cell to Present NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline and Update on GDA-201 at Today's Virtual R&D Day ● Company recently filed an IND application for GDA-201; FDA placed the application on Clinical Hold pending modifications to donor eligibility procedures and ster ...

2019-09-08 - Could Gamida Cell Ltd.'s (NASDAQ:GMDA) Investor Composition Influence The Stock Price?

Every investor in Gamida Cell Ltd. (NASDAQ:GMDA) should be aware of the most powerful shareholder groups. Insiders often own a large ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$30.3M19725%N/A
#2
$7.5M20615%$140.2M
#3
$68.7M21838%N/A
#4
$15M226-12%$197.5M
#5
$82M276-39%N/A